*ST长药
(300391)
| 流通市值：11.98亿 | | | 总市值：11.98亿 |
| 流通股本：3.50亿 | | | 总股本：3.50亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 105,452,067.42 | 70,574,999.01 | 45,795,675.76 | 111,625,132.67 |
| 营业收入 | 105,452,067.42 | 70,574,999.01 | 45,795,675.76 | 111,625,132.67 |
| 二、营业总成本 | 209,776,662.36 | 144,912,647.94 | 106,127,907.23 | 355,147,875.33 |
| 营业成本 | 104,623,622.01 | 67,993,403.43 | 47,500,988.09 | 118,791,058.48 |
| 税金及附加 | 1,723,407.46 | 1,148,311.44 | 614,069.95 | 2,474,641.66 |
| 销售费用 | 8,510,497.48 | 5,588,918.39 | 2,939,791.68 | 12,980,244.36 |
| 管理费用 | 61,983,325.09 | 41,777,722.83 | 19,053,546.04 | 102,594,239.69 |
| 研发费用 | 2,350,342.36 | 1,791,273.13 | 1,046,230.8 | 7,897,062.02 |
| 财务费用 | 30,585,467.96 | 26,613,018.72 | 34,973,280.67 | 110,410,629.12 |
| 其中:利息费用 | 30,051,345.46 | 26,416,943.71 | 35,220,018.1 | 111,173,734.74 |
| 其中:利息收入 | 13,484.23 | 9,403.97 | 3,009.72 | 61,300.42 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | 0 |
| 加:投资收益 | 2,200,000 | 2,200,000 | 2,900,000 | -4,391,497.52 |
| 资产处置收益 | -655,228.63 | -10,628.26 | -101,726.14 | -303,874.08 |
| 资产减值损失(新) | -252,335.84 | -252,335.84 | - | -448,552,187.19 |
| 信用减值损失(新) | -144,012,333.16 | -69,700,418.76 | -31,953,818.21 | -634,652,760.69 |
| 其他收益 | 728,192.91 | 616,211.88 | 315,367.93 | 627,652.88 |
| 四、营业利润 | -246,316,299.66 | -141,484,819.91 | -89,172,407.89 | -1,330,795,409.26 |
| 加:营业外收入 | 122,940.72 | 91,963.2 | 65,209.47 | 148,503.87 |
| 减:营业外支出 | 469,552.43 | 467,082.08 | 289,356.56 | 97,068,868.66 |
| 五、利润总额 | -246,662,911.37 | -141,859,938.79 | -89,396,554.98 | -1,427,715,774.05 |
| 减:所得税费用 | -401,780.71 | -351,402.51 | - | 10,960,677.8 |
| 六、净利润 | -246,261,130.66 | -141,508,536.28 | -89,396,554.98 | -1,438,676,451.85 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -246,261,130.66 | -141,508,536.28 | -89,396,554.98 | -1,438,676,451.85 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -209,732,156.62 | -116,353,783.05 | -60,812,317.13 | -627,961,728.5 |
| 少数股东损益 | -36,528,974.04 | -25,154,753.23 | -28,584,237.85 | -810,714,723.35 |
| 扣除非经常损益后的净利润 | -209,287,579.27 | -116,477,762.04 | -62,639,023.43 | -569,394,644.22 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.6 | -0.33 | -0.17 | -1.79 |
| (二)稀释每股收益 | -0.6 | -0.33 | -0.17 | -1.79 |
| 九、综合收益总额 | -246,261,130.66 | -141,508,536.28 | -89,396,554.98 | -1,438,676,451.85 |
| 归属于母公司股东的综合收益总额 | -209,732,156.62 | -116,353,783.05 | -60,812,317.13 | -627,961,728.5 |
| 归属于少数股东的综合收益总额 | -36,528,974.04 | -25,154,753.23 | -28,584,237.85 | -810,714,723.35 |
| 公告日期 | 2025-10-27 | 2025-08-26 | 2025-04-28 | 2025-04-21 |
| 审计意见(境内) | | | | 带强调事项段的无保留意见 |